Corvus Pharmaceuticals, Inc.
CRVSNext catalyst
Soquelitinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Get an email about CRVS's next catalysts
Track Corvus Pharmaceuticals (CRVS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CRVS Earnings Report
EPS Est: $-0.21 | FQ end Sep/2026 | Call: amc
Soquelitinib Phase 2 Est. Readout (SIERRA1)
Estimated primary completion for Soquelitinib trial (NCT07441395) in Atopic Dermatitis. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Soquelitinib | Phase 3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | - | - |
Frequently asked questions
What is in Corvus Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Corvus Pharmaceuticals, Inc.'s (CRVS) pipeline across Phase 3. Its lead program is Soquelitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Corvus Pharmaceuticals, Inc.'s next FDA catalyst?→
Corvus Pharmaceuticals, Inc.'s (CRVS) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRVS biotech catalysts?→
Add CRVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Corvus Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.